Physician profile
Mechell S Smith
NPI 1538272679
$11,920.76
in general payments reported to CMS, 2019-2025
40 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,077 · 2022: $3,185 · 2023: $3,482 · 2024: $1,979 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,571 · Education: $87.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,571.19 |
| Education | $87.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,583.85 | 2021-2025 | |
| Novo Nordisk INC | $1,443.85 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Corcept Therapeutics | $1,196.59 | 2021-2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $727.73 | 2021-2025 | Farxiga, Airsupra, Tagrisso |
| Lilly USA, LLC | $725.18 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $683.46 | 2021-2024 | |
| Amgen INC. | $644.36 | 2021-2024 | Otezla, Repatha, Evenity |
| Jazz Pharmaceuticals INC. | $534.17 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $365.17 | 2021-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $351.01 | 2021-2024 | |
| Pfizer INC. | $345.35 | 2021-2025 | |
| Glaxosmithkline, LLC. | $300.36 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.15 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $253.24 | 2021-2022 | |
| Harmony Biosciences LLC | $249.99 | 2022-2024 | Wakix |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $243.58 | 2021-2024 | Trintellix |
| Abbott Laboratories | $240.46 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $180.33 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $173.82 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $166.46 | 2021-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Mylan Specialty L.P. | $160.23 | 2021-2024 | Yupelri, Yupelri |
| Kowa Pharmaceuticals America, INC. | $137.70 | 2021-2024 | Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.82 | 2021-2024 | Xifaxan |
| Astellas Pharma US INC | $125.42 | 2021-2023 | Veozah |
| Sunovion Pharmaceuticals INC. | $117.69 | 2021-2022 | |
| Amarin Pharma, INC. | $98.12 | 2021-2022 | |
| Exact Sciences Corporation | $85.95 | 2023-2024 | Cologuard Collection Kit |
| Avadel Cns Pharmaceuticals, LLC | $53.25 | 2024 | Lumryz |
| Axsome Therapeutics, INC. | $48.33 | 2023 | Sunosi |
| Dexcom, INC. | $45.86 | 2022-2023 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $36.39 | 2024 | Crysvita |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.35 | 2023-2024 | Caplyta |
| Eisai INC. | $33.09 | 2021-2022 | |
| Insulet Corporation | $30.33 | 2021 | |
| Medtronic, INC. | $25.73 | 2025 | Avalus |
| Xeris Pharmaceuticals, INC. | $23.30 | 2024 | Recorlev |
| Idorsia Pharmaceuticals US INC | $16.52 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $16.30 | 2023 | Gemtesa |
| Ultragenyx Pharmaceutical INC. | $16.26 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mechell Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.